Camurus

Lund, Sweden - 12 June 2024 - As of 12 June 2024, a total of 673,200 options in Camurus AB's employee stock options program (ESOP) 2021/2024 have been exercised for the corresponding number of shares, at an exercise price of SEK 263.50 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 177,388,200.

A number of employees and senior executives of Camurus have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related to the ESOP exercise, or in such number of shares that corresponded to the number of employee stock options exercised by the participant.

The exercise period for ESOP 2021/2024 ends on 16 December 2024.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

The information was submitted for publication at 4.15 pm CEST on 12 June 2024.